These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29911955)

  • 41. Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations.
    Elliott J; van Katwyk S; McCoy B; Clifford T; Potter BK; Skidmore B; Wells GA; Coyle D
    Pharmacoeconomics; 2019 Oct; 37(10):1261-1276. PubMed ID: 31201643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study.
    Borghs S; Thieffry S; Noack-Rink M; Dedeken P; Hong LS; Byram L; Logan J; Chan J; Kiri V
    BMC Neurol; 2017 Mar; 17(1):59. PubMed ID: 28335764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.
    Fishman J; Kalilani L; Song Y; Swallow E; Wild I
    J Manag Care Spec Pharm; 2018 Sep; 24(9):929-938. PubMed ID: 29486142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of open transforaminal lumbar interbody fusion (OTLIF) versus minimally invasive transforaminal lumbar interbody fusion (MITLIF): a systematic review and meta-analysis.
    Droeghaag R; Hermans SMM; Caelers IJMH; Evers SMAA; van Hemert WLW; van Santbrink H
    Spine J; 2021 Jun; 21(6):945-954. PubMed ID: 33493680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis.
    Messori A; Trippoli S; Becagli P; Cincotta M; Labbate MG; Zaccara G
    Eur J Clin Pharmacol; 1998 Feb; 53(6):421-7. PubMed ID: 9551700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies.
    Thangaratinam S; Marlin N; Newton S; Weckesser A; Bagary M; Greenhill L; Rikunenko R; D'Amico M; Rogozińska E; Kelso A; Hard K; Coleman J; Moss N; Roberts T; Middleton L; Dodds J; Pullen A; Eldridge S; Pirie A; Denny E; McCorry D; Khan KS
    Health Technol Assess; 2018 May; 22(23):1-152. PubMed ID: 29737274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cost-minimisation analysis of the pharmacological treatment of epilepsy in Spain].
    Rubio M; Lizán L; Badia X; Escartín-Siquier AE; López-Trigo J; Rufo-Campos M; Echarri E
    Rev Neurol; 2006 Mar 1-15; 42(5):257-64. PubMed ID: 16538587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis.
    Aranda-Reneo I; Rodríguez-Sánchez B; Peña-Longobardo LM; Oliva-Moreno J; López-Bastida J
    Value Health; 2021 Mar; 24(3):431-442. PubMed ID: 33641778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic Evaluation of Medically Assisted Reproduction: A Methodological Systematic Review.
    Van Muylder A; D'Hooghe T; Luyten J
    Med Decis Making; 2023; 43(7-8):973-991. PubMed ID: 37621143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy.
    Heaney DC; Shorvon SD; Sander JW
    Epilepsia; 1998; 39 Suppl 3():S19-25. PubMed ID: 9593232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.
    Helmers SL; Duh MS; Guérin A; Sarda SP; Samuelson TM; Bunker MT; Olin BD; Jackson SD; Faught E
    Eur J Paediatr Neurol; 2012 Sep; 16(5):449-58. PubMed ID: 22261080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
    Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
    JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacoeconomics of the new antiepileptic drugs.
    Heaney D
    Epilepsia; 1999; 40 Suppl 8():25-31. PubMed ID: 10563592
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacoeconomic evaluation of medical treatment of epilepsy: where do we stand?
    Levy P
    Acta Neurol Belg; 1999 Dec; 99(4):239-46. PubMed ID: 10674141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
    Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
    Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States.
    Choi H; Mohit B
    Epilepsia; 2019 Jul; 60(7):1472-1481. PubMed ID: 31158306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and economic burden of breakthrough seizures.
    Divino V; Petrilla AA; Bollu V; Velez F; Ettinger A; Makin C
    Epilepsy Behav; 2015 Oct; 51():40-7. PubMed ID: 26255884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.